AAAmish Asthana

Amish Asthana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amish Asthana has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Giuseppe Orlando

    Wake Forest School of Medicine, Winston Salem, USA

    6 shared publications
  • Giuseppe Orlando

    Departement of Surgery, Section of Transplantation, Wake Forest School of Medicine, Winston Salem, NC, USA; Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA

    4 shared publications
  • Quentin Perrier

    Departement of Surgery, Section of Transplantation, Wake Forest School of Medicine, Winston Salem, NC, USA; Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA; Univ. Grenoble Alpes, INSERM U1055, Department of Pharmacy, Grenoble Alpes University Hospital, LBFA, Grenoble, France

    4 shared publications
  • Alice Tomei

    Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, USA

    3 shared publications
  • Arunkumar Rengaraj

    Departement of Surgery, Section of Transplantation, Wake Forest School of Medicine, Winston Salem, NC, USA; Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA

    3 shared publications
  • Lori Byers

    Departement of Surgery, Section of Transplantation, Wake Forest School of Medicine, Winston Salem, NC, USA; Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA

    3 shared publications

Latest Publications

  • Open Access

    Route-aware modeling for mitochondrial transplantation in barrier-limited organs

    by Melanie Walker, Giuseppe Orlando, Amish Asthana, Michael R. Levitt, Gabriel C. Oniscu

    Background: Mitochondrial transplantation is an emerging regenerative therapy aimed at preventing ischemia-reperfusion injury by restoring oxidative metabolism in vulnerable tissues. Early clinical studies have demonstrated feasibility in pediatric myocardium and procedural safety in adult stroke patients, yet dose selection in non-cardiac, barrier-limited organs remains empiric and lacks a physiology-based framework. Establishing a quantitative approach to mitochondrial dosing is therefore a critical barrier to clinical translation. Methods: We developed a physiologically grounded computational model to estimate route-specific input dose requirements for brain, spinal cord, and kidney. The model integrates organ-level parameters including tissue mass, regional perfusion or cerebrospinal flow, permeability-surface area product, and extraction efficiency. A benchmark dose of 2 × 10⁶ mitochondria per gram of viable parenchymal tissue, derived from validated cardiac protocols, was applied across delivery scenarios. Results: Here we show that extraction fraction is the dominant determinant of procedural feasibility, with up to twofold divergence from cardiac-derived estimates in central nervous system targets under reduced barrier permeability. Under stroke-relevant conditions with blood brain barrier permeability, required input doses converge toward myocardial benchmarks. Conclusions: This framework provides a quantitative foundation for route-aware mitochondrial dose planning and supports rational translational trial design in ischemia-reperfusion injury and related conditions.

  • Open Access

    Scalable 3D bioprinting of human islets in a pancreatic decellularized extracellular matrix-enriched bioink for beta-cell replacement therapy

    by Wonwoo Jeong, Quentin Perrier, Arunkumar Rengaraj, Lori Byers, Grisell C. Gonzalez, Emma Peveri, Jake Miller, Rita Bottino, Alexei V. Mikhailov, Christopher Fraker, et al.


  • Open Access

    Adenosine as a modulator of human islet function and hypoxic tolerance

    by Quentin Perrier, Adam Jones, Timothy Sganga, Lori Byers, Thomas Ritchey, Sandrine Lablanche, Christopher Fraker, Kelsey H. Fisher-Wellman, Alice A. Tomei, Rita Bottino, et al.

    Islet transplantation hold promises as a cell therapy for managing type 1 diabetes, but its effectiveness remains limited due to early graft loss caused by hypoxia and associated stressors. Identifying strategies to enhance islet resilience is imperative for improving clinical outcomes. We hypothesized that mitigating this injury requires shifting focus from augmenting oxygen supply to reducing the cellular metabolic demand. Adenosine (AD), an endogenous purine nucleoside with immunomodulatory and metabolic regulatory roles, emerges as a candidate to mitigate these challenges. This study evaluates the impact of AD on human islet (HI) viability, function, and metabolic suppression under hypoxic stress (1% O 2 ). Results demonstrated that AD at 1 mM induced a transient reduction in insulin content without impairing viability or functional indices (stimulation index, insulin secretion). These changes were reversible within 96 h of withdrawal. Preconditioning HI with 1 mM AD prior to 48-h hypoxia preserved both viability and glucose-stimulated insulin secretion, mitigating functional losses up to 48 h post-reperfusion. These findings establish AD preconditioning as an effective, reversible approach to reduce islet metabolic demand and enhance hypoxia tolerance during the early post-transplantation period. Furthermore, AD can be readily integrated into various stages of beta-cell replacement workflow, including islet culture, encapsulation, and 3D bioprinting. Overall, AD-mediated metabolic downregulation offers a novel strategy for mitigating ischemia-reperfusion injury, paving the way for more efficient and resilient cell-based therapies for beta-cell replacement.

  • Top Cited Papers

    Therapeutic and mechanistic insights on mitochondrial transplantation in kidney disease

    by James D. McCully, Aybuke Celik, Amish Asthana, Giuseppe Orlando

    Acute kidney injury (AKI) and chronic kidney disease (CKD) are major contributors to global morbidity and mortality, with limited treatment options beyond supportive care. Mitochondrial dysfunction is a shared feature of both conditions, driving impaired energy production, oxidative stress and cell death. Owing to its reliance on oxidative phosphorylation, the kidney is especially vulnerable to ischaemia–reperfusion injury, a leading cause of AKI and a risk factor for long-term loss of kidney function. Persistent mitochondrial damage contributes to the transition from AKI to CKD, and strategies aimed at restoring mitochondrial health, therefore, have therapeutic potential. Here, we focus on mitochondrial transplantation, a therapeutic approach that delivers viable, respiratory-competent mitochondria to injured tissue to support recovery. Mitochondria for transplantation can be isolated from a variety of sources (autologous or allogeneic) without triggering an immune, autoimmune or inflammatory response, or a reaction to damage-associated molecular patterns. Isolated mitochondria can be delivered by intra-arterial injection, and, once in the target organ, they are rapidly integrated into the cells through endocytosis. Mitochondrial transplantation supports the restoration of mitochondrial function and associated signalling pathways, promoting enhanced organ function and cellular viability. Several preclinical studies have demonstrated improved kidney function, reduced inflammation and preserved mitochondrial structure following mitochondrial therapy in models of ischaemia.


  • Open Access

    Dose Modeling for Mitochondrial Transplantation in Barrier-Limited Tissues

    by Melanie Walker, Giuseppe Orlando, Amish Asthana, Gabriel C. Oniscu, Michael R. Levitt

    Mitochondrial transplantation is an emerging regenerative therapy aimed at preventing ischemia– reperfusion injury (IRI) by restoring oxidative metabolism in vulnerable tissues. While early clinical studies have demonstrated feasibility in pediatric myocardium and safety in adult stroke patients, dosing strategies remain undefined for barrier-limited organs where autoregulation, restricted perfusion, and anatomical constraints limit parenchymal uptake. We developed a physiologically grounded computational model to estimate route-specific input dose requirements for brain, spinal cord, and kidney. The model integrates organ-level parameters including tissue mass, regional perfusion or cerebrospinal flow, permeability–surface area product, and extraction efficiency. A benchmark dose of 2 × 10 6 mitochondria per gram, derived from validated cardiac protocols, was applied across delivery scenarios. Sensitivity analysis explored the effects of extraction fraction and tissue mass. Route-adjusted input requirements diverged quantitatively from cardiac-derived estimates, with up to 2-fold increases in central nervous system (CNS) targets and approximately 20% higher dosing required for the kidney. This framework provides a quantitative foundation for translational dose planning in IRI and related conditions.

  • Open Access

    State of the Art of Bioengineering Approaches in Beta-Cell Replacement

    by Jake Miller, Quentin Perrier, Arunkumar Rengaraj, Joshua Bowlby, Lori Byers, Emma Peveri, Wonwoo Jeong, Thomas Ritchey, Alberto Maria Gambelli, Arianna Rossi, et al.

    Purpose of the Review: Despite recent advancements in technology for the treatment of type 1 diabetes (T1D), exogenous insulin delivery through automated devices remains the gold standard for treatment. This review will explore progress made in pancreatic islet bioengineering within the field of beta-cell replacement for T1D treatment. Recent Findings: First, we will focus on the use of decellularized extracellular matrices (dECM) as a platform for pancreatic organoid development. These matrices preserve microarchitecture and essential biochemical signals for cell differentiation, offering a promising alternative to synthetic matrices. Second, advancements in 3D bioprinting for creating complex organ structures like pancreatic islets will be discussed. This technology allows for increased precision and customization of cellular models, crucial for replicating native pancreatic islet functionality. Finally, this review will explore the use of stem cell-derived organoids to generate insulin-producing islet-like cells. While these organoids face challenges such as functional immaturity and poor vascularization, they represent a significant advancement for disease modeling, drug screening, and autologous islet transplantation. Summary: These innovative approaches promise to revolutionize T1D treatment by overcoming the limitations of traditional therapies based on human pancreatic islets.


  • Open Access

    Comprehensive biocompatibility profiling of human pancreas-derived biomaterial

    by Amish Asthana, Amanda Gallego, Quentin Perrier, Tamara Lozano, Lori N. Byers, Jun Ho-Heo, Wonwoo Jeong, Riccardo Tamburrini, Arunkumar Rengaraj, Deborah Chaimov, et al.

    Introduction: The importance of the extracellular matrix (ECM) to pancreatic islets has been clearly demonstrated, as isolated islets grown in culture or transplanted, quickly lose viability and function after their matrix associations have been stripped away during the isolation process. Therefore, recapitulating the islet niche is a critical objective to move the field of islet transplantation forward.Methods: As a first step to recreating the islet microenvironment, we have recently developed a detergent-free decellularization method to obtain a decellularized solubilized ECM (dsECM) powder from human pancreas. We have also shown that this gentler method (compared to traditional detergent-based methods) allows for thorough preservation of the molecular fingerprint of the innate organ. Furthermore, incorporation of dsECM in alginate-microencapsulated human islets, showed a significant increase in insulin secretion, compared to both free and alginate-only encapsulated islets. However, it is also essential to test the interaction of dsECM with multiple cell types to establish its safety for transplantation.Results and discussion: Herein, we present a comprehensive in vitro evaluation of the cytotoxicity, hemocompatibility and immunocompatibility of dsECM to establish a concentration range where it deemed safe and biocompatible. Furthermore, dsECM-based bioinks were coaxially bioprinted and the resulting construct's biocompatibility and vascularization potential were also evaluated in vivo.


  • Top Cited Papers
    Open Access

    Predicting proximal tubule failed repair drivers through regularized regression analysis of single cell multiomic sequencing

    by Nicolas Ledru, Parker C. Wilson, Yoshiharu Muto, Yasuhiro Yoshimura, Haojia Wu, Dian Li, Amish Asthana, Stefan G. Tullius, Sushrut S. Waikar, Giuseppe Orlando, et al.

    Renal proximal tubule epithelial cells have considerable intrinsic repair capacity following injury. However, a fraction of injured proximal tubule cells fails to undergo normal repair and assumes a proinflammatory and profibrotic phenotype that may promote fibrosis and chronic kidney disease. The healthy to failed repair change is marked by cell state-specific transcriptomic and epigenomic changes. Single nucleus joint RNA- and ATAC-seq sequencing offers an opportunity to study the gene regulatory networks underpinning these changes in order to identify key regulatory drivers. We develop a regularized regression approach to construct genome-wide parametric gene regulatory networks using multiomic datasets. We generate a single nucleus multiomic dataset from seven adult human kidney samples and apply our method to study drivers of a failed injury response associated with kidney disease. We demonstrate that our approach is a highly effective tool for predicting key cis- and trans-regulatory elements underpinning the healthy to failed repair transition and use it to identify NFAT5 as a driver of the maladaptive proximal tubule state.


  • Decellularized human pancreatic extracellular matrix-based physiomimetic microenvironment for human islet culture

    by Amish Asthana, Deborah Chaimov, Riccardo Tamburrini, Carlo Gazia, Amanda Gallego, Tamara Lozano, Jun-Ho Heo, Lori N. Byers, Alice Tomei, Christopher A. Fraker, et al.


  • Open Access

    Mitochondria Transplantation Mitigates Damage in an In Vitro Model of Renal Tubular Injury and in an Ex Vivo Model of DCD Renal Transplantation

    by Andrea Rossi, Amish Asthana, Chiara Riganti, Sargis Sedrakyan, Lori Nicole Bs Byers, John Vmd Robertson, Ryan S. Senger, Filippo Montali, Cristina Grange, Alessia Dalmasso, et al.

    Objectives: To test whether mitochondrial transplantation (MITO) mitigates damage in two models of acute kidney injury (AKI). Summary Background Data: MITO is a process where exogenous isolated mitochondria are taken up by cells. As virtually any morbid clinical condition is characterized by mitochondrial distress, MITO may find a role as a treatment modality in numerous clinical scenarios including AKI. Methods: For the in vitro experiments, human proximal tubular cells were damaged and then treated with mitochondria or placebo. For the ex vivo experiments, we developed a non-survival ex vivo porcine model mimicking the donation after cardiac death (DCD) renal transplantation scenario. One kidney was treated with mitochondria, while the mate organ received placebo, before being perfused at room temperature for 24 hours. Perfusate samples were collected at different time points and analyzed with Raman spectroscopy. Biopsies taken at baseline and 24 hours were analyzed with standard pathology, immunohistochemistry and RNA sequencing analysis. Results: In vitro, cells treated with MITO showed higher proliferative capacity and ATP production, preservation of physiological polarization of the organelles and lower toxicity and reactive oxygen species production. Ex vivo, kidneys treated with MITO shed fewer molecular species, indicating stability. In these kidneys, pathology showed less damage while RNAseq analysis showed modulation of genes and pathways most consistent with mitochondrial biogenesis and energy metabolism and downregulation of genes involved in neutrophil recruitment, including IL1A, CXCL8, and PIK3R1. Conclusions: MITO mitigates AKI both in vitro and ex vivo.